A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Several antibody–drug conjugates (ADCs), using ... containing immunochemotherapy regimens in relapsed/refractory B-cell lymphoma and leukemia. Other ADCs directed against other B-cell lineage ...

The main character 'Gwansik' in the recently popular Netflix drama 'I've been tricked' has died of multiple myeloma, making ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

At the beginning of the year Incyte paid $750m to Morphosys for the CD-19 targeting antibody, which has been approved in combination with BMS’ Revlimid (lenalidomide) for adults with relapsed or ...

professor of Stem Cell Transplantation & Cellular Therapy The trial's novel approach uses Affimed's AFM13 bispecific antibody, which is designed to bind to CD16A on NK cells and CD30 on lymphoma ...